Showing results for "of science" in Policy & Administration

Based on the film by acclaimed documentary filmmaker Ken Burns, The Mayo Clinic: Faith, Hope, Science chronicles the history of this unique organization, from its roots as an unlikely partnership between a country doctor and a Franciscan order of nuns to its position today as a worldwide model for patient care, research, and education. The book demonstrates how the institution’s remarkable 150-year history continues to inspire the way medicine is practiced there today.

Organizations have invested $30–40 billion in AI. According to MIT (2025), 95% produced no measurable return. Only 5% made it into daily workflows. If you're reading this, you're trying not to become that statistic—or you already are. The problem isn't bad technology. Most AI failures don't begin at scale. They begin during pilots, when early success builds confidence without revealing risks that surface once AI enters real workflows and decisions under pressure.

From New York Times best-selling author Robert F. Kennedy, Jr., comes a science-based call for the immediate removal of the dangerous mercury-containing preservative Thimerosal from vaccines. Over a decade ago, following a sharp rise in developmental disorders such as autism and ADHD, the mercury-containing preservative Thimerosal was widely believed to have been eliminated from vaccine supplies in the United States and abroad.

Well-heeled American corporations have long had a financial stake in undermining scientific consensus and manufacturing uncertainty. In The Triumph of Doubt, former Obama and Clinton official David Michaels details how corrupt science becomes public policy - and where it's happening today.

A hard-hitting critique of how managed care and the selective use of science to privilege quick-fix therapies have undermined in-depth psychotherapy—to the detriment of patients and practitioners In recent decades there has been a decline in the quality and availability of psychotherapy in...

A healthcare AI expert examines how artificial intelligence can either undermine or enhance the doctor-patient relationship, offering frameworks to keep medicine human-centered. Subjects to Sovereigns explores what happens when the most powerful AI systems in medicine make decisions about patients who are never really heard? For most of modern medicine, patients have been treated as data points inside someone else’s system. Artificial intelligence risks locking that pattern in forever.

We have entered what is called the "biological century" and a new biopolitics has emerged to address the implications for America's collective value system, our well-being, and ultimately, our future. The Body Politic is the first book to recognize and assess this new force in our political landscape - one that fuels today's culture wars and has motivated politicians of all stripes to reexamine their platforms.

American Health—Who Gets Paid examines the pricing system that quietly governs US medicine—and explains why what gets paid for gets done. Rather than focusing on politics, personalities, or technology, the book looks at the underlying economics of medical work: how care is valued, who sets those values, and how payment rules shape clinical behavior, institutional priorities, and innovation.

Government, industry, and the medical profession, however, have a mixed record when it comes to framing policies and generating knowledge to address drug use and misuse. In Strange Trips, Lucas Richert investigates the myths, meanings, and boundaries of recreational drugs, palliative care drugs, and pharmaceuticals as well as struggles over product innovation, consumer protection, and freedom of choice in the medical marketplace.

The media constantly bombard us with news of health hazards lurking in our everyday lives. But many of these hazards turn out to have been greatly overblown. According to author and epidemiologist Geoffrey C. Kabat, this hyping of low-level environmental hazards leads to needless anxiety and confusion on the part of the public as to which exposures have important effects on health and which are likely to have minimal or no effect.

Life sciences companies deliver the most innovative, life changing products in the world. Period. And yet, when it comes to delivering impactful experiences built around patients and healthcare professionals that leverage omnichannel capabilities to commercialize these therapies, our industry struggles to transform (to put it diplomatically). Why? It's because we never took the time to properly educate ourselves on the basic building blocks of omnichannel capabilities and advanced concepts on customer-driven experiences that address stakeholder needs.